1. An association between myasthenia gravis and Crohn's disease has been reported previously in only one patient.

2. Other causes of megaesophagus include myasthenia gravis , lead poisoning , and Addison's disease.

3. Myasthenia Gravis is caused by an acetylcholine receptor deficiency at the neuromuscular junction. Ptosis may be an early and prominent sign of the disease.

4. BACKGROUND: Myasthenia gravis is an autoimmune disease in which autoantibodies interfere with neuromuscular transmission.

5. Conclusion Patients with myasthenia gravis received treatment of immunoadsorption have better clinical effective, It is worthy of promotion.

6. Objective To report the clinical features of myasthenia gravis ( MG ) combined with Lambert - Eaton myasthenic syndrome ( LEMS ).

7. Clinical for muscular dystrophy, myasthenia gravis, muscular dystrophy, polymyositis, motor neuron disease, as atrophy disease syringomyelia.

8. Objective To improve clinicians'understanding of nephrotic syndrome and myasthenia gravis as adverse events of penicillamine(D-PA).

9. Conclusion Medical history of infantile myasthenia gravis and positive of neostigmine test are important diagnostic bases of this disease.

10. Myasthenia gravis (MG) is a disorder of the neuromuscular junction that affects communication between the motor neuron and the innervated muscle cell.

11. Objective To discuss the influence of different nursing interventions on the quality of life in myasthenia gravis(MG)patients after thymectomy, and to find the effective education methods.

12. Objective The pathological changes on neuromuscular junction (NMJ) in the patients with myasthenia gravis (MG) or LambertEaton myasthenia syndrome (LEMS) were investigated comparatively.

13. Certain antibiotics such as colistin, streptomycin, kanamycin and other drugs have aggravated the effects of myasthenia gravis, it should be noted.

14. clinical significance of the Ryanodine receptor antibody ( RyR - Ab ) and interferon - α antibody ( IFN - α Ab ) in myasthenia gravis ( ...

15. Objective To Discuss the effect of thoracoscope assisted small incision to treat children's myasthenia gravis.

16. Objective:To assess the efficacy of thymectomy for the treatment of ocular myasthenia gravis.

17. Aim : To investigate the role of thymus of patients with myasthenia gravis ( MG ).

18. Objective Repetitive nerve stimulation of anconeus muscle(anconeus RNS) was explored in diagnosis of myasthenia gravis.

19. Objective : To discuss the interventional factors of death in MG ( myasthenia gravis ) patients to decrease the death rate.

20. Objectives:To explore the clinical effect and safety of staphylococcal protein A immunoadsorption on myasthenia gravis patients.

21. Objective To investigate the effect of immature dendritic cells ( iDCs ) on experimental autoimmune myasthenia gravis ( EAMG ).

22. In this paper we reported different methods of anesthesia influencing the outlook of thymectomy for 16 cases of thymoma complication with myasthenia gravis.

23. Objective:To provide morphological data of thymic percutaneous paracentesis for intervention treatment of myasthenia gravis.

24. Objective : To observe the curative effect of TCM therapy on myasthenia gravis of ocular type.

25. Conclusion: Extended thymectomy is an effective surgical procedure for patients with myasthenia gravis and it should be considered as early as possible.

26. This article reported the nursing experience of applying Roy's adaptation model (RAM) to assist a school-age child with myasthenia gravis in PICU.

27. Objective To analyze operative method and prognosis of thymectomy for treatment of crisis of myasthenia gravis.

28. The ministernotomy approach was designed to perform thymectomy for myasthenia gravis in order to lessen surgical trauma and made cosmetically effectiveness.

29. This article reviews study progresses of neotype immunodepressant of myasthenia gravis by collecting its lastest related information.

30. Objective: To investigate the therapeutic effect and safety of immunoadsorption therapy in patients with myasthenia gravis.

31. There were not the records of myasthenia gravis in TCM documents. According to its primary symptom, myasthenia gravis is belonged to scope of flaccidity syndrome usually.

32. Objective : To investigate extraocular muscles ( EOM ) susceptibility to myasthenia gravis ( MG ).

33. Objective To evaluate the effectiveness of thymectomy for myasthenia gravis(MG)and the relative factors for postoperative myasthenic crisis and the treatment outcome of thymectomy.

34. Objective To observe the therapeutic effect of immunodepressant after thymusectomy in patients with myasthenia gravis (MG).

35. Objective To introduce the surgical method and evaluate the efficacy of extended thymectomy through partial sternotomy for the treatment of myasthenia gravis.

36. Objective To evaluate the long-term out. e of thymectomy . bined with corticosteroid therapy for myasthenia gravis (MG) with thymoma.

37. Myasthenia gravis(MG) is an autoimmune disease which choline receptor antibody mediates, cell immunity depends on and addiment participates.

38. ObjectiveTo explore the application of plasma exchange in myasthenia gravis (MG) patients with thymectomy , and to evaluate its curative effects.

39. Objective To study the outcome of surgical treatment of myasthenia gravis(MG)by thymectomy via video-assisted thoracoscopic surgery(VATS)and partial sternotomy.

40. Objective To summarize the experiences in perioperative management of thymectomy for myasthenia gravis (MG).

41. Objiective To introduce the nursing experience of myasthenia gravis crisis after thymectomy.

42. Objective : To review the causes and treatment of myasthenia gravis ( MG ) crisis after thymectomy.

43. interferon - α antibody ( IFN - α Ab ) in myasthenia gravis ( MG ) patients.

44. Method 7 cases of clinical data about myasthenia gravis crisis after thymectomy were retrospected and analyzed.

45. Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular transmission, usually recognized with ocular complaints or generalized muscle weakness.